A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Part of paid clinical trials in Fountain Valley, California.

Sponsor
Genentech, Inc.
Study ID
NCT07541079
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Giredestrant — DRUG
    Participants will receive giredestrant at a dose of 30 mg orally once daily on Days 1-28 of each 28-day cycle for up to 4.5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).

Study Details

The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance. Giredestrant will be administered as adjuvant endocrine therapy for participants with low-, medium-, and high-risk, Stage I-III, histologically confirmed, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (eBC), as defined by the investigator. Participants will enroll if considered to be intolerant to a prior adjuvant AI therapy.

Key Dates

First listed
Apr 21, 2026
Start date
Aug 15, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2032
Completion
Jun 30, 2034

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Giredestrant

Primary Outcome Measure

Incidence of Participants Who Have Discontinued Giredestrant for Any Reason at 12 Months [ Time Frame: At 12 months ]

Central Contacts

  • Reference Study ID Number: GO46747 https://forpatients.roche.com/ No attachments to email below.
    888-662-6728 (U.S. Only)
    [email protected]
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Locations (1)

FacilityCityStateZIPSite coordinators
Orange Coast Medical CenterFountain ValleyCalifornia92708-6728-

Find similar trials in Fountain Valley, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Orange Coast Medical Center· Fountain Valley, CA

Related Studies